The role of combination chemotherapy has not yet been established in unresectable locally advanced pancreatic cancer (LAPC) lacking dedicated randomized trials.
Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer - A GISCAD phase II randomized trial / Cascinu, Stefano; Berardi, Rossana; Bianco, Roberto; Bilancia, Domenico; Zaniboni, Alberto; Ferrari, Daris; Mosconi, Stefania; Spallanzani, Andrea; Cavanna, Luigi; Leo, Silvana; Negri, Francesca; Beretta, Giordano D; Sobrero, Alberto; Banzi, Maria; Morabito, Alberto; Bittoni, Alessandro; Marciano, Roberta; Ferrara, Domenica; Noventa, Silvia; Piccirillo, Maria C; Labianca, Roberto; Mosconi, Cristina; Casadei Gardini, Andrea; Gallo, Ciro; Perrone, Francesco. - In: EUROPEAN JOURNAL OF CANCER. - ISSN 1879-0852. - 148:(2021), pp. 422-429. [10.1016/j.ejca.2021.02.023]
Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer - A GISCAD phase II randomized trial
Marciano, Roberta;Gallo, Ciro;Perrone, Francesco
2021
Abstract
The role of combination chemotherapy has not yet been established in unresectable locally advanced pancreatic cancer (LAPC) lacking dedicated randomized trials.| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S0959804921001064-main.pdf
accesso aperto
Tipologia:
Versione Editoriale (PDF)
Licenza:
Copyright dell'editore
Dimensione
890.78 kB
Formato
Adobe PDF
|
890.78 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
